Latest Financial Performance News

DigitalX Limited posted a larger loss for FY25 despite an 18% revenue increase, driven by digital asset appreciation and a bold Bitcoin accumulation strategy.

Paradigm Biopharmaceuticals marked FY25 with the launch of its global Phase 3 trial for its osteoarthritis drug iPPS, backed by strong FDA protocol approval and a $41 million funding facility. The company also broadened its pipeline with the acquisition of Pentacoxib™, targeting early-stage OA.

KneoMedia has narrowed its FY25 net loss by 38%, driven by cost controls and a strategic shift to its scalable KneoScience EdTech platform. The company also secured a $700,000 order for FY26, signaling growing traction in the US education market.

Oliver's Real Food reported a 25.8% increase in net loss to $2.91 million for FY2025 despite a 23.5% rise in core earnings before impairments, driven by operational restructuring and store closures.

First Graphene Limited reported a 13% reduction in net loss for FY25 alongside steady revenue and expanding commercial demand for its PureGRAPH products.

Powerhouse Ventures Limited reported a striking 348.8% jump in profit after tax to $1.82 million for FY25, driven by strategic acquisitions and a robust investment portfolio. The company’s first operating cash profit and growth in net tangible assets signal a turning point in its transformation.

Skin Elements Limited reported a 13% revenue increase and a 20% reduction in net loss for FY2025, as it progresses commercial roll-out of its natural biotech products including ECO-Nurture and SuprCuvr.

Rhythm Biosciences has significantly reduced its annual loss by 44%, boosted by a 91% rise in other income, while launching a new wholly owned subsidiary, RHY GeneType Pty Ltd.

OncoSil Medical reported a $15.1 million loss for FY25 amid strong revenue growth and significant regulatory milestones, supported by over $14 million in capital raises to fuel its global expansion.

Orthocell Ltd reported a record $9.23 million revenue for FY25, driven by strong sales of its nerve repair and dental products, alongside securing US FDA clearance for its flagship nerve repair device Remplir. The company is poised for accelerated growth as it expands its global commercial footprint.

xReality Group (XRG) reports a landmark FY25 with 36% revenue growth driven by its Operator XR platform and a major US law enforcement contract. The company’s strategic shift towards immersive training technology signals robust momentum into FY26.

Cann Group Limited reported a significant 56% reduction in net loss for FY25, driven by cost cuts and strong growth in dried flower sales, even as revenue declined due to shifting product preferences. The company faces going concern challenges but is actively pursuing debt refinancing and operational improvements.